Navigation Links
Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today it expects total revenues for the fourth quarter of 2011 will be approximately $92.7 million, bringing expected full year  2011 revenues to approximately $343.5 million.

The expectations for revenues in the fourth quarter of 2011 reflect an increase of approximately 14 percent versus revenues of $81.2 million in the fourth quarter a year ago.  Medical segment revenues increased approximately 20 percent in the fourth quarter of 2011 versus the same period a year ago. The expected revenues for all of fiscal 2011 reflect an increase of approximately 17 percent over revenues of $294.1 million in fiscal 2010.

"We are pleased with these record quarterly and annual revenues as our medical segment business continued to demonstrate solid growth—led by a strong performance in our FFR (Fractional Flow Reserve) disposable business, which increased 37 percent in the quarter versus the fourth quarter a year ago. Our IVUS (Intravascular Ultrasound) business performed to our expectations. However, due to continued softness in telecom infrastructure spending in key international geographies, we experienced a greater than anticipated reduction in Axsun Industrial segment revenues, which were approximately $1.5 million in the fourth quarter of 2011 versus revenues of $5.1 million in the fourth quarter a year ago, or a decline of approximately 70 percent," said Scott Huennekens, president and chief executive officer.

"We continue to be optimistic about the market opportunities for our current offerings—especially FFR —as well as  products in our pipeline as healthcare providers face increasing demand to demonstrate comparative effectiveness and medical necessity and as professional guidelines elevate the use of IVUS and FFR," he added.

The company said it was providing the estimated revenues for 2011 in advance of meetings with the investment community and its presentation at the 30th Annual J.P. Morgan Healthcare Conference. The company's presentation will occur at 9:30 a.m., Pacific Standard Time (12:30 p.m., Eastern Standard Time), Tuesday, January 10. A webcast of the presentation will be available through the conference website at and via the company's website at

The company's complete fourth quarter and full year 2011 financial results and guidance for 2012 will be provided in a press release, as well as a conference call and publically available webcast, in late February. Details for the earnings press release data, conference call and webcast will be provided in a subsequent press release.

About Volcano

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Specifically, statements concerning Volcano's expected revenues, revenue growth and financial results for the fourth quarter and year ended December 31, 2011, are forward-looking statements involving risks and uncertainties. These statements reflect estimates based on information available at this time and are being made prior to the completion of Volcano's accounting close procedures, including an audit by its independent accountants, for the year ended December 31, 2011, and could therefore differ from the actual reported results in Volcano's Form 10-K, which the company expects to file in February 2012. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risk that Volcano's current revenue estimates for its fourth quarter and fiscal year ended December 31, 2011 could be inaccurate, risks inherent in Volcano's international operations that may adverse impact its revenues and financial results, including the impact of the 2011 tsunami in Japan,  the effect of competitive and economic factors, and the company's reaction to those factors, on purchasing decisions with respect to the company's products, the pace and extent of market adoption of the company's products and technologies, the inherent uncertainty in the process of obtaining regulatory approval or clearance for Volcano's products or devices, the success of Volcano's growth strategies, risks related to foreign currency fluctuations and other worldwide economic factors,  timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly  report on Form 10-Q for the quarter  ended September 30, 2011, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
2. Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcanos Precision Guided Therapy Technologies
3. Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011
4. Volcano Reports 18 Percent Increase in Total Third Quarter Revenues
5. Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors
6. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
7. Volcano Corporation Announces Presentations at Upcoming Investor Conferences
8. Volcano Reports 22 Percent Increase in Second Quarter Medical Segment Revenues and Earnings per share of $0.09
9. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
10. Volcano Corporation Presentation at William Blair Conference to be Webcast
11. Volcano Corporation Presentation at Goldman Sachs Conference to be Webcast
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):